TVB-3664 is an experimental compound primarily investigated for its potential in treating neurodegenerative diseases, particularly Alzheimer’s disease. It functions as a modulator of tau protein, targeting the pathological aggregation of tau into neurofibrillary tangles, which are a hallmark of Alzheimer’s and other tauopathies. By inhibiting or reducing the formation of these abnormal aggregates, TVB-3664 aims to preserve neuronal function and slow cognitive decline. The compound has shown promise in preclinical models, where it demonstrated the ability to reduce tau pathology and improve cognitive performance. Its development is part of a broader effort to create disease-modifying therapies for Alzheimer’s, as opposed to treatments that only address symptoms. Due to its targeted mechanism, TVB-3664 may also have applications in other tau-related disorders such as progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD). Currently, TVB-3664 is under evaluation in early-stage clinical trials to assess safety, pharmacokinetics, and preliminary efficacy in humans. If successful, it could become a key therapeutic agent in the fight against neurodegenerative conditions with tau pathology.